Generic drug status of tremelimumab

Tremelimumab is a monoclonal antibody targeting cellular immune checkpoints and is a CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) inhibitor. The drug was jointly developed by AstraZeneca and MedImmune and was first launched in Europe and the United States under the trade name Imjudo. Its original design is to activate and enhance the anti-tumor immune response of T cells by blocking the binding of CTLA-4 to its ligands, thereby achieving immune control of a variety of solid tumors. Currently, the drug is mainly used in combination with the PD-L1 inhibitor Durvalumab (trade name: Imfinzi) to treat unresectable hepatocellular carcinoma (uHCC) and metastatic non-small cell lung cancer (NSCLC). After being approved by the US FDA in 2022, it quickly became a new focus in the field of immunotherapy.

As far as generic drugs are concerned, as of2025, temsitumumab is still an innovative biological drug within the patent protection period, and there are no officially approved biosimilars or generic versions worldwide. Because the production process of monoclonal antibodies is complex and involves high-tech links such as cell line screening, protein folding, and glycosylation modification, its imitation is much more difficult than traditional small molecule chemical drugs. Current public information shows that European, American and some biopharmaceutical companies are conducting early-stage research and development of biosimilars, but they have not yet entered the clinical verification stage, and no products have been submitted for regulatory approval.

In mainland China, temsitumumab has not yet been officially launched, so there is currently no original drug for sale in the domestic market, and there are no approved domestic generic versions. According to AstraZeneca's global strategic layout, it is expected that the drug will gradually apply for registration in the Asian market in the future, but in the short term it will still need to rely on imported original drug supply.

From the perspective of the global drug competition landscape, the launch of generic drugs of temsitumumab may be delayed until around 2030. Biosimilars may not be available until its patent protection expires. For patients, original drug treatment can currently be obtained through overseas medical channels or patient assistance programs of multinational pharmaceutical companies.

Reference: https://www.drugs.com/mtm/tremelimumab.html